Distribution agreements for Matritech's cancer test:
This article was originally published in Clinica
Matritech has formed two marketing agreements for NMP22, its bladder cancer test, with Finnish company Wallac's German subsidiary and an unnamed Italian company. Matritech expects to release details concerning the Italian distributor by the end of the month. A distribution agreement with Boehringer Ingelheim, which was struck in 1994 (see Clinica No 617, p13), has been terminated by mutual consent, Matritech says. The test kit is an EIA to measure the amount of NMP in stabilised urine (see Clinica No 704, p 17).
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.